Artificial heart: Carmat, French flag of Medtech, collapses despite clinical successes
Carmat, pioneer of the artificial heart, has just filed for bankruptcy after failing to bring together 3.5 million euros. © Shutershock
It was presented as one of the flagships of French medical tech, a symbol of ingenuity mixing robotics, biomaterials and on -board intelligence. But this Monday, Carmat officially filed for bankruptcy, unable to bring together the funds necessary to maintain its activity. A new one as rough as it is absurd at a time when clinical advances accumulated and when the locations continued to progress.
Carmat files for bankruptcy: French medical tech loses a pioneer of the artificial heart
The cleaver fell. This morning, Carmat announced that it had filed a declaration of cessation of payments and requested the opening of a receivership procedure. The company, which has been developing the artificial heart Aeson for over 15 years, has failed to bring together the 3.5 million euros which were essential to hold it until the end of June.
And yet the paradox is cruel. On the clinical level, Carmat had just crossed a symbolic milestone: 100 patients located in Europe, a commercial dynamic launched outside the European Union, reimbursable trials in France … but without cash, not immediately.
Carmat announces today a declaration of cessation of payments and request the opening of a receivership procedure with the Commercial Court of Versailles.
The Aeson project, a complex synthesis of biomaterials, sensors and on -board intelligence, required massive financial support. The company estimated its needs at 35 million euros for the next twelve months. Neither the investors, the state nor the donations came to fill this hole.
The Carmat action is suspended on the stock market. And if the Commercial Court of Versailles accepts the opening of the receivership, there will remain a chance – thin – to save the business, by finding a buyer.
Remains the human. Patients equipped with the Aeson heart will have to continue to live with a device whose technical support now depends on a suspended structure. For a project that promised to change the situation in terminal heart failure, the return to earth is brutal. And like other French nuggets, from Pixium to DNA Script, Carmat recalls that in France, innovation knows how to shine, but struggles to breathe without lasting support.
Want to save even more? Discover Our promo codes Selected for you.
